MILAN–( COMPANY WIRE)– Newron.
Pharmaceuticals SpA. (” Newron”) [Ticker: SIX: NWRN], a.
biopharmaceutical business focused on the development of unique therapies.
for patients with illness of the central worried system (CNS) and discomfort,.
today announced that Stefan Weber, CEO, will provide at the Jefferies.
2016 Healthcare Conference in New York, NY on Tuesday, June 7, 2016 at.
3:00 pm ET.
Health care Conference includes a comprehensive variety of public and.
private healthcare companies throughout the biopharmaceuticals, life.
sciences, health care services, healthcare IT and medical innovation.
sectors. The conference addresses financial investment chances and discuss.
the systems driving healthcare in the US and worldwide.
About Newron Pharmaceuticals
Newron (SIX: NWRN) is a.
biopharmaceutical company concentrated on the development of novel therapies.
for patients with illness of the central worried system (CNS) and pain.
The Company is locateded in Bresso near Milan, Italy. Xadago.
( Safinamide) has received marketing authorization for the treatment of.
Parkinson’s illness in the European Union and Switzerland and is.
commercialized by Newron’s Partner Zambon. United States WorldMeds holds the.
commercialization rights in the United States. Meiji Seika has the rights to.
develop and advertise the substance in Japan and other essential Asian.
areas. In addition to Xadago for Parkinson’s disease, Newron has.
a strong pipeline of promising treatments for rare disease clients at.
numerous phases of clinical development, including sarizotan for clients.
with Rett syndrome and ralfinamide for patients with specific unusual pain.
indications. Newron is likewise establishing NW-3509 as the potential first.
add-on treatment for the treatment of clients with favorable signs of.
schizophrenia.For more information, please visit: www.newron.com.